Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Past Team (4)Update
Funding Rounds (5) - $120.5MUpdate
NGN Capital is a venture capital firm specializing in investments in the US and European...
Clarus Ventures is a life sciences venture capital firm.
Life Sciences VC
Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in...
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that...
Lehman Brothers is a global financial services firm headquartered in New York City. It was...
San Francisco Bay Area
Lucerne Valley, CA